Biotechs beat Big Pharma as patients lose faith with giants

Anyone who tells you that there's no such thing as bad publicity never worked in the pharma business. A new survey shows that GlaxoSmithKline ($GSK) and some of its pharma rivals have seen their negative ratings soar in the wake of damaging admissions as patients lose faith with some of the biggest drug peddlers. Running against the trend: Gilead ($GILD) and Lundbeck, which got top marks for transparency and integrity. Novartis ($NVS) came in third. Story

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.